.jpeg)
The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of a COVID-19 vaccine candidate, developed by the University of Oxford, in the country. Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr VG Somani late night on August 2 after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.
The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of a COVID-19 vaccine candidate, developed by the University of Oxford, in the country. Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr VG Somani late night on August 2 after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.
417.jpeg)
10.jpeg)
40.jpeg)
100.jpeg)
416.jpeg)
5.jpeg)
4.jpeg)
6.jpeg)
5.jpeg)
